The association of XPG and MMS19L polymorphisms response to chemotherapy in osteosarcoma. - Wikidata - wikimedia - TriplyDB

The association of XPG and MMS19L polymorphisms response to chemotherapy in osteosarcoma.

The association of XPG and MMS19L polymorphisms response to chemotherapy in osteosarcoma.

http://www.wikidata.org/entity/Q37382606

about

Effect of ABCB1 polymorphism on the clinical outcome of osteosarcoma patients after receiving chemotherapy Association study between XPG Asp1104His polymorphism and colorectal cancer risk in a Chinese population.Predictive value of XPG rs2296147T>C polymorphism on clinical outcomes of cancer patients.Association between common polymorphisms in ERCC gene and prognosis of osteosarcoma in patients treated with chemotherapy: a meta-analysis.

P2860

Q34002029-516BFB5F-7A38-4495-AD91-B8D811013E5D Q34375597-CA82E20A-3B71-4D18-9556-5A6B2C8EBA37 Q37662309-F8B059A0-BCA3-4AB9-AEE8-8CFBDECC6DD5 Q55313372-1C3B891E-7475-4D74-B9E7-36BEB0C0CCF7

P2860

The association of XPG and MMS19L polymorphisms response to chemotherapy in osteosarcoma.

http://www.wikidata.org/entity/Q37382606

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on September 2013

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

The association of XPG and MMS19L polymorphisms response to chemotherapy in osteosarcoma.

@en

The association of XPG and MMS19L polymorphisms response to chemotherapy in osteosarcoma.

@nl

type

label

The association of XPG and MMS19L polymorphisms response to chemotherapy in osteosarcoma.

@en

The association of XPG and MMS19L polymorphisms response to chemotherapy in osteosarcoma.

@nl

prefLabel

The association of XPG and MMS19L polymorphisms response to chemotherapy in osteosarcoma.

@en

The association of XPG and MMS19L polymorphisms response to chemotherapy in osteosarcoma.

@nl

P1433

Q37382606-F4788BF9-4D26-4467-8979-07AD839E3784

P1476

Q37382606-311F3D2B-0F28-4D94-B09B-A23835254713

P2093

Q37382606-39300F29-118E-4841-9E25-11EBD2256D24

Q37382606-58826E93-03A0-484A-8F8F-170E9A9EBB95

Q37382606-A13F2257-758F-40F9-954B-D30A47646F77

Q37382606-A8980AB7-54A9-4FC3-88AF-92C91258B598

Q37382606-CA87EE8A-0842-4BB4-B63D-9A4A7DDC5951

Q37382606-E939BE1B-E03D-4C51-8932-65230F012989

Q37382606-F4ECDA16-2967-43CD-B140-DDA3FB300FA0

Q37382606-F67D9E35-6DF0-4C5F-96C1-FA6A497B7510

P2860

Q37382606-126B437C-B627-4906-B2C5-C534C885EA98

Q37382606-13294FC9-7275-4079-B4BD-DDC8EB6CF364

Q37382606-23ABA563-1103-4891-BAAE-88E49F9F0CE2

Q37382606-2F175F8B-7262-4E81-8CD7-010E01589D57

Q37382606-3864943D-8607-4207-98DA-863BB73AFAB6

Q37382606-4949CAC3-420C-44DC-AA56-C29EBE1B2908

Q37382606-5F6C4978-5462-4277-8B2F-F5678C2D4E8A

Q37382606-74D32752-87B0-41E9-A5CB-F0C98A9DD2C0

Q37382606-7A0A6524-DD6D-4E04-AA12-42B7762A7558

Q37382606-897B486A-C24B-4AD6-89EF-9A066E377536

P304

Q37382606-7B008EBE-1257-4E3C-BB30-3AE253AEE4DF

P31

Q37382606-EE553630-7AAE-47D7-B168-2E5D2D042191

P356

Q37382606-8A46C326-6366-4478-8C6E-057D9175D1D2

P433

Q37382606-39176375-FBDB-401C-B4E7-E40812E338A7

P478

Q37382606-8D224A8D-D3F2-4C1C-BF8F-25795DA6154A

P577

Q37382606-20F45EC5-0335-4C2D-8D88-147EA72321F0

P698

Q37382606-75FD4AD1-98CC-48C3-9D2E-DEA5BAE4130A

P921

Q37382606-9B490991-EDA8-43F3-B05B-4DF8F5A24526

P932

Q37382606-63F74931-4249-4F7D-8DE1-4B841653AA93

P356

P1433

Pakistan Journal of Medical Sciences

P1476

The association of XPG and MMS19L polymorphisms response to chemotherapy in osteosarcoma

@en

P2093

Hua Qin

http://www.w3.org/2001/XMLSchema#string

Jin-Jie Zhong

http://www.w3.org/2001/XMLSchema#string

Li-Bin Yang

http://www.w3.org/2001/XMLSchema#string

Lin Yang

http://www.w3.org/2001/XMLSchema#string

Qing-Lan Zhou

http://www.w3.org/2001/XMLSchema#string

Xiao-Lin Geng

http://www.w3.org/2001/XMLSchema#string

Yi-Lei Zhao

http://www.w3.org/2001/XMLSchema#string

Yu-Zhen Dong

http://www.w3.org/2001/XMLSchema#string

P2860

Common variations in ERCC2 are associated with response to cisplatin chemotherapy and clinical outcome in osteosarcoma patients.

Reporting results of cancer treatment

Association between single nucleotide polymorphisms (SNPs) and toxicity of advanced non-small-cell lung cancer patients treated with chemotherapy.

Nucleotide excision repair gene variants and association with survival in osteosarcoma patients treated with neoadjuvant chemotherapy.

Identification of MMS19 domains with distinct functions in NER and transcription.

Primary bone osteosarcoma in the pediatric age: state of the art.

Molecular mechanisms of resistance and toxicity associated with platinating agents.

Biology and therapeutic advances for pediatric osteosarcoma.

Nucleotide excision repair pathway polymorphisms and pancreatic cancer risk: evidence for role of MMS19L.

Irofulven cytotoxicity depends on transcription-coupled nucleotide excision repair and is correlated with XPG expression in solid tumor cells.

P304

1225-1229

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.12669/PJMS.295.3747

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

29

http://www.w3.org/2001/XMLSchema#string

P577

2013-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24353725

http://www.w3.org/2001/XMLSchema#string

P921

P932

3858920

http://www.w3.org/2001/XMLSchema#string